JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Johnson & Johnson (JNJ)  announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing deal for Kaken’s STAT6 program includes global rights to its lead candidate, KP-723.How the Licensing Deal for the AD Program Benefits JNJThe licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pa ...